$EXEL FDA Approval Filing and New Phase 3 Trials Planned for Cabo

Exelixis (NASDAQ:EXEL) is a cancer biotech which is focused on the late-stage development of its wholly-owned (after regaining all rights to the compound from $BMY in JUN 2010) cabozantinib "cabo" (formerly XL184) (MET, VEGFR2, and RET inhibitor anti-cancer agent) w/ a summary of the clinical development status for cabo outlined below.

Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA / Clinical Trades

- Analyst Reports with consistently updated summaries

- Run-Up Valuation Studies

- Gameplan Videos

- Live Chat

- Weekly Newsletter
- Email / SMS (Text Message) Alerts of critical news

- BioRunUp's and Mike Havrilla's Trading Accounts

- BioRunUp Forums

- A More Detailed FDA Calendar
- Increased Organization of Tracking Upcoming Catalysts

- A Unique Ratings System to Grade Catalysts

- A Growing Focus on Upcoming Clinical Trial Catalysts
- Direct Email Communication

- Affiliate Program, earn $50 for every referral who joins

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.